Garvicin ML (GarML) is a circular bacteriocin produced by Lactococcus garvieae DCC43. The recently published draft genome of this strain allowed determination of the genetic background for bacteriocin production. Bioinformatic analysis identified a gene cluster consisting of nine open reading frames likely involved in the production of and immunity to GarML. The garA gene encodes the bacteriocin precursor, garX a large transmembrane protein, garBCDE a putative immunity protein (garB) followed by an ATPase and two transmembrane proteins, and garFGH a putative ABC transporter complex. Functional genetic analysis revealed that deletion of garFGH had no effect on sensitivity to or production of GarML. In contrast, deletion of garBCDE or inactivation of garX resulted in high-level sensitivity to GarML and completely abolished production of active bacteriocin. Mass spectrometry of culture supernatants revealed that wild-type cultures contained the mature circular form as well as the linear forms of the bacteriocin, both with and without the three-amino-acid leader sequence, while bacteriocin-negative mutants contained only the linear forms. These results indicate that cleavage of the leader peptide precedes circularization and is likely performed by a functional entity separate from the GarML gene cluster. To our knowledge, this is the first conclusive evidence for these processes being separated in time. Loss of immunity and antimicrobial activity in addition to our inability to detect the circular bacteriocin in the ⌬garBCDE and garX::pCG47 mutants demonstrate that both these units are indispensable for GarML biosynthesis as well as immunity. Furthermore, the results indicate that these genes are implicated in the circularization of the bacteriocin and that their functions are probably interlinked.
B
acteriocins are ribosomally encoded antimicrobial peptides that are produced by bacteria and display activity against other bacterial strains (1). The production of bacteriocins is a widespread trait among lactic acid bacteria, which produce numerous bacteriocins varying in size, structure, physicochemical properties, and inhibitory spectrum. These bacteriocins are classified into two main classes: the class I bacteriocins, which contain posttranslationally modified amino acids, and the class II bacteriocins, which are heat-stable unmodified bacteriocins (2) .
Garvicin ML (GarML) is a potent bacteriocin produced by Lactococcus garvieae DCC43 (3, 4) that is a member of the class IIc circular bacteriocins, characterized by their N-to C-terminal covalent link forming a circular backbone (5) . These antimicrobial peptides are attracting much interest because of their physicochemical characteristics, namely, high pH tolerance and thermal stability as well as resistance to proteases, which make this class of bacteriocins highly promising as drugs or natural preservatives for diverse applications in medicine and food technology.
Circular bacteriocins are synthesized as linear precursors with a leader peptide of variable size (2 to 35 amino acid residues) that is cleaved off at some point during the maturation process, which also includes circularization of the peptide and export out of the producer cell (5) . Although several of the circular bacteriocins have now been genetically characterized, the enzymes responsible for the different steps of maturation and the mechanisms and potential coupling of the processes are still unknown (6) .
To date, there have been characterized 9 circular bacteriocins, which are subdivided into two classes (2) . Subclass i contains cationic peptides with a high isoelectric point (pI close to 10) and comprises the majority of the known circular bacteriocins: garvicin ML (3), enterocin AS-48 (7), circularin A (8), carnocyclin A (9), uberolysin (10), lactocyclicin Q (11), and leucocyclicin (12) . These peptides display limited sequence identity, but homology modeling based on the known structures of enterocin AS-48 and carnocyclin A indicates that the members of this subclass share a conserved three-dimensional (3D) structure (13) . This structure consists of 4 or 5 ␣-helices forming a compact globular bundle around a hydrophobic core, where several positively charged residues located on the surface of the structure are thought to attract the peptides to the membranes of the target cells (13) . Subclass ii circular bacteriocins differ in that they share high sequence identity, contain more acidic residues, and hence have a lower isoelectric point (pI close to 5). These include gassericin A (14) and butyrivibriocin AR10 (15) . Previously, the circular peptide subtilosin A (16) was considered to belong to this subclass; however, this and a few other circular peptides, including the sporulation killing factor (SKF) of Bacillus thuringiensis (17) , contain thioether linkages and are structurally and genetically distinct from the circular bacteriocins. These peptides have therefore been reclassified as members of a novel subclass of peptides known as the sactibiotics (18) .
For most of the circular bacteriocins, the respective gene clusters have been described (19) (20) (21) (22) (23) . A minimal set of 5 to 7 genes is generally required for production of and immunity to the bacteriocin, including the bacteriocin structural gene and a gene encoding a small hydrophobic high-pI peptide which constitutes the cognate immunity protein that provides a basal immunity level (19) . Furthermore, 2 to 4 genes encoding putative membrane proteins, one of which contains the domain of unknown function 95 (DUF95) as well as an ATPase, make up the minimal set of genes for biosynthesis and immunity. These membrane proteins may form a transporter complex responsible for exporting the peptide out of the producer cell. Additionally, most clusters contain 3 or 4 genes thought to encode another ABC transporter, which in several cases has been shown to be nonessential for bacteriocin production and immunity (19, 20, 22) but may, however, provide an increased level of immunity and enhance the production of the bacteriocin (21) . Although the sequence similarities between the encoded proteins of different circular bacteriocin gene clusters are generally low, there appears to be strong functional conservation in the biosynthetic machinery and mechanisms of this class of bacteriocins. However, the precise roles of the encoded proteins in the biosynthesis and export of and immunity to circular bacteriocins remain to be elucidated.
In this study, we identified the gene cluster responsible for production of the circular bacteriocin garvicin ML (GarML) in the producer strain L. garvieae DCC43 and functionally analyzed the production of this bacteriocin at the gene and protein levels, which has provided new insights into the biosynthesis of subclass i circular bacteriocins.
MATERIALS AND METHODS
Bacterial strains and plasmids. The bacterial strains and plasmids used in this study are listed in Table S1 in the supplemental material. Lactococci were routinely grown in M17 medium (Oxoid, Hampshire, United Kingdom) supplemented with 0.4% (wt/vol) glucose (GM17) at 30°C. Escherichia coli strains used for cloning purposes were grown in lysogeny broth (LB) at 37°C with shaking at 225 rpm. Tetracycline was added to a final concentration of 5 g ml Ϫ1 when required for selection of Lactococcus transformants. Ampicillin was added to a final concentration of 100 g ml Ϫ1 , and kanamycin to 50 g ml Ϫ1 , when required for selection of E. coli transformants.
Bacteriocin purification and assays. The bacteriocin garvicin ML was concentrated 100-fold from the supernatant of the producing strain L. garvieae DCC43, grown in MRS medium (Oxoid, Hampshire, United Kingdom), by precipitation with 45% (wt/vol) ammonium sulfate and subsequently resuspended in sterile deionized water. Bacteriocin activity was determined using microtiter plate assays (MPA) as described previously (24) , where one bacteriocin unit (BU) was defined as the amount of bacteriocin required to produce 50% growth inhibition in 200 l of culture against the indicator strain Lactococcus lactis IL1403 (25) . Production of and immunity to bacteriocin were assayed by agar diffusion tests (ADTs), where 1 l ml Ϫ1 of the overnight culture of the indicator strain was added to GM17 soft agar and poured into plates. After solidification and drying, circular wells were punched out and bacteriocin solution added. The plates were incubated overnight at the appropriate temperature, and the area of growth inhibition was subsequently measured.
Bioinformatic analysis. The entire genome of the bacteriocin producer L. garvieae DCC43 was previously sequenced and assembled de novo by Gabrielsen et al. (26) . From the known nucleotide sequence of the GarML structural gene (GenBank accession no. GU205098) (3), the GarML precursor gene (garA) was localized to contig 1 of the L. garvieae DCC43 draft genome (GenBank accession no. AMQS00000000). Open reading frames (ORFs) in the draft genome located close to the GarML precursor gene were predicted using CLC DNA workbench 6.0.2, allowing for all possible start codons, using the bacterial genetic code (11) and including small (Ͼ50 codons) ORFs.
Searches for similarity of the putative proteins encoded in the GarML cluster to proteins of other circular bacteriocin clusters (known sequences) or to other known proteins (nonredundant protein database) were performed by protein BLAST alignment (27) , with an E value cutoff of 0.01. Conserved domains were identified similarly through the NCBI Conserved Domain Database (28) , with an E value threshold of 0.01.
The physicochemical properties of the putative proteins, including theoretical isoelectric point (pI), average molecular weight, aliphatic index (AI), and grand average of hydropathicity (GRAVY), were predicted using ProtParam (29) . The putative cellular localizations of the proteins were predicted using PSORTb v3.0.2 (30) .
For the proteins with significant structural homologues in the Protein Data Bank (PDB), i.e., GarML, the 3D structure of the protein was modeled based on Tcoffee multiple alignment (31) and SWISS-model homology modeling (32) using the closest homolog as the template, which for GarML is the solution structure of carnocyclin A (PDB accession no. 2KJF). For the proteins which had no close sequence or structural homologues, the secondary structure was predicted using either MEMSAT3-SVM (33) , for the putative transmembrane proteins, or the Jpred server (34) , for the soluble proteins.
Cloning and functional analysis of the GarML gene cluster. Cloning techniques, in general, were performed according to the methods of Sambrook and Russell (35) . Cloning was performed mainly in E. coli before introduction of plasmids into lactococci. Transformations of lactococci were performed as described by Holo and Nes (36) . Plasmid isolation was carried out using an EZNA plasmid miniprep kit (Omega Bio-Tek, Inc.) or a Qiagen Plasmid Midi kit (Qiagen). Restriction enzymes, calf intestinal alkaline phosphatase, T4 polynucleotide kinase, and T4 DNA ligase (New England BioLabs Inc.) were used according to the supplier's instructions. Oligonucleotides were supplied by Invitrogen Life Technologies. PCR was performed using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific), and PCR products were purified using NucleoSpin extract II (Macherey-Nagel).
Vectors used for deletion of the two operons (garBCDE and garFGH) were created by PCR amplification of approximately 1-kb fragments flanking the respective operons, using primers listed in Table S1 in the supplemental material. The flanking sequences of each operon were subjected to splicing by overhang extension PCR using the outer primer pairs, and the resulting fragments were subsequently ligated into pCR-Blunt IITOPO. A SnaBI/SmaI fragment of pAS222 (37) containing the lactococcal thermosensitive replicon repA and a tetracycline resistance marker was then blunt-end cloned into the SmaI site, creating deletion vectors pCG44 and pCG45. The deletion vectors were introduced into L. garvieae DCC43, and selection for deletion of garBCDE and garFGH by double crossover was carried out as described previously (38) . PCR and sequencing were used to confirm the deletion of each operon.
To inactivate garX, a 600-bp internal fragment of this gene (primer pair garX-F/garX-R) was cloned into pAS222, creating vector pCG47. As a control, a similarly sized fragment of an intergenic region (primer pair IGR-F/IGR-R) was cloned into pAS222 to create pCG48. The vectors were transformed into L. garvieae DCC43, and selection for integration was performed as described previously. The correct integration of the vectors at either locus was confirmed by PCR and sequencing, while incubation at 37°C combined with antibiotic selection was used for all subsequent assays.
The L. garvieae DCC43 ⌬garFGH, ⌬garBCDE, and garX::pCG47 mutants were functionally characterized with respect to growth, immunity, and production of bacteriocin. Growth was evaluated by 24-h kinetic measurement of growth (optical density at 600 nm [OD 600 ]) of 100-fold-diluted cultures in GM17 medium by use of a SPECTROstar Nano microplate reader (BMG Labtech). Immunity to GarML was quantified by MPA and ADT against concentrated GarML from the wild-type producer strain supernatant, while production of bacteriocin was measured by ADT using L. lactis IL1403 as the indicator strain.
Preparation of supernatant for mass spectrometry (MS). Cell cultures were grown to stationary phase before separation of supernatant and cells by centrifugation at 6,500 ϫ g for 10 min. Supernatants were concentrated by ammonium sulfate precipitation, as described previously, and resuspended in 1 ml of 10 mM Tris-HCl buffer (pH 7.5). Supernatant samples were subsequently filtered, desalted, and concentrated using columns with a 10-kDa size limit (Amicon Ultra-2 centrifugal filter unit with Ultracel-10 membrane; Millipore) followed by centrifugation at 6,000 ϫ g for 10 min and washing twice with 10 mM Tris-HCl (pH 7.5) before elution.
In-tip digestion. Before use, Stage columns were prepared, conditioned, and equilibrated as described previously (39) . A volume of 2.5 l immobilized trypsin slurry (Poroszyme; Applied Biosystems) was added, and the trypsin part of the column was packed/equilibrated by pressing through two 10-l volumes of 50 mM (NH 4 )HCO 3 . The protein solution was mixed with a 0.1ϫ volume of 500 mM (NH 4 )HCO 3 and pressed through the column. The column (Stage column plus immobilized trypsin) was rinsed twice with 10 l 0.1% trifluoroacetic acid (TFA), which simultaneously inactivated the enzyme. Tryptic peptides were eluted from the column by using 70% acetonitrile (ACN)-0.03% TFA. Prior to MS analysis, the eluate was evaporated and the peptides dissolved in 10 l loading buffer.
LC-MS analysis. The peptides were separated in a 50-cm by 75-minternal-diameter Acclaim PepMap column by use of a linear 3 to 40% ACN gradient over 90 min, with a flow rate of 300 nl min Ϫ1 . A nano-liquid chromatography (nano-LC) (Dionex Ultimate 3000 UPLC) system was interfaced with a Q Exactive quadrupole orbitrap mass spectrometer (Thermo Scientific) acquiring positive-ion mass spectra in data-dependent (dd) mode. For every full scan at resolution 70,000, 10 MS/MS scans at resolution 17,500 were recorded. The dd settings were as follows: automatic gain control (AGC) target, 1 ϫ 10 5 ions; maximum injection time, 50 ms; normalized collision energy, 30; and isolation width, 2.0 m/z.
Nucleotide sequence accession number. The new ORFs and updated annotation of the GarML gene cluster were appended to the draft genome of L. garvieae DCC43 (GenBank accession no. AMQS00000000).
RESULTS

Sequence and bioinformatic analyses of the GarML gene cluster.
The genome of the GarML producer strain L. garvieae DCC43 was previously sequenced and de novo assembled to allow determination of the genetic determinants behind GarML production and immunity (26) . A 264-bp fragment encompassing the structural gene of the GarML precursor (189 bp) and some surrounding sequence was previously determined by reverse genetics (3), and from this known nucleotide sequence (GenBank accession no. GU205098), the GarML precursor gene was localized to contig 1 of the L. garvieae DCC43 draft genome (GenBank accession no. AMQS00000000). This contig is 175.6 kb long and contains chromosomal genes (e.g., genes for a ribosomal protein cluster, tRNA synthetase, and the RNA polymerase alpha subunit), thus establishing that the GarML gene cluster is chromosomally encoded.
In the vicinity of the GarML precursor gene, henceforth referred to as garA, in accordance with suggested nomenclature (40), we identified eight ORFs that appeared to be involved in production of and immunity to GarML, based on similarity to gene clusters of other circular bacteriocins (Fig. 1) . A single ORF named garX is located 61 bp downstream of and on the same strand as garA, while the remaining ORFs, garBCDE and garFGH, are located upstream, on the opposite strand. The predicted physicochemical characteristics, secondary structure, subcellular localization, and conserved domains of the putative proteins encoded by the GarML gene cluster are summarized in Table 1 .
The genetic organization suggests that garA and garX form independent transcriptional units. However, garBCDE and garFGH appear to constitute operons that are regulated by translational coupling, as the end of garC overlaps (by 11 bp) the start of garD, and the garF, garG, and garH ORFs also overlap by 1 and 4 bp, respectively (Fig. 1) .
The putative protein encoded by garB was predicted to constitute a small (6,514.12 Da), hydrophobic, high-pI protein with a predicted secondary structure of two alpha-helices, likely to be membrane localized. These characteristics concur with those of immunity proteins of other circular bacteriocins (19, 20, 22) , and we therefore predicted garB to encode the cognate immunity protein to GarML.
Using BLAST to search for homologues of the putative proteins encoded by the GarML gene cluster (Table 1) , specifically among other circular bacteriocins, we found that GarC is similar to CclT, CirD, and AS-48D, of the carnocyclin A, circularin A, and enterocin AS-48 gene clusters, respectively, which are all predicted soluble ATP-binding proteins. The protein displays a high degree of homology to members of the P-loop NTPase domain superfamily, containing a nucleotide binding site (formed by Walker A, Walker B, Q loop, D loop, and H loop motifs) as well as an ABC transporter signature motif (LSGGQ). The evidence thus suggests that garC encodes the ATPase subunit of an ABC transporter complex.
GarD displays homology to CclC of the carnocyclin A gene cluster. The protein was predicted to consist of four transmembrane helices, indicating that it is a membrane protein. Interestingly, garD was found to contain a conserved domain of unknown function, DUF95, which has been found in the gene clusters of almost all genetically characterized circular bacteriocins to date. DUF95 proteins share a similar overall structure of several predicted transmembrane helices and are believed to constitute integral membrane proteins, but the function of this family of proteins is unknown (Pfam database accession no. PF01944).
The proteins encoded by the garFGH operon display a high degree of similarity to AS-48FGH and CclFGH of the enterocin AS-48 and carnocyclin A gene clusters, which are thought to encode ABC transporter complexes involved in bacteriocin immunity (21) . GarH displays a high degree of homology to the SalY multidomain (permease component of an ABC-type antimicrobial peptide transport system) and is predicted to have a total of four transmembrane helices, three of which are constituted by the C-terminal FtsX domain found in many permease proteins. The protein also contains a MacB-like PCD, i.e., a periplasmic core domain found in a variety of ABC transporters. GarG (like GarC) displays a high degree of homology to members of the P-loop NTPase domain superfamily, contains the same motifs, and is therefore thought to encode the ATPase component of this ABC transporter complex. GarF, on the other hand, is predicted to contain a leader sequence and displays similarity to the RND MFP multidomain, which is a membrane fusion protein component of the RND (resistance, nodulation, and cell division) family of transporters. These proteins, including GarF, contain biotinyl/ lipoyl-like domains. Based on these results, we propose that gar-FGH encodes an ABC transporter, with garG encoding a soluble ATP-binding protein, garF encoding the transmembrane permease component, and garH encoding an accessory periplasmic protein.
The perhaps most enigmatic gene in the GarML gene cluster is garX, which is the only ORF carried on the same strand as the GarML precursor gene. It is a relatively large gene (1,434 bp) that encodes a 56,564-Da protein. Secondary structure prediction suggests a structure of 8 to 12 transmembrane helices separated by intracellular and extracellular segments of various sizes. This putative protein has no significant sequence similarity to any known proteins or conserved domains, including those of other circular bacteriocin clusters, and as such, bioinformatic analysis cannot give any more clues to the possible function of this protein. However, similar large putative membrane proteins, which could have related functions, are found in several other circular bacteriocin gene clusters (Fig. 1) .
Comparative analysis of the GarML gene cluster. Comparative analysis of the GarML gene cluster to the gene clusters of other circular bacteriocins reveals that although there is limited sequence identity of the encoded proteins (average of 20 to 30% pairwise identity), there are many shared traits and commonalities between the encoded proteins (Fig. 1) . The GarML gene cluster appears to be most similar to the enterocin AS-48 (GenBank accession no. Y12234 and AJ438950) and carnocyclin A (GenBank accession no. EU624394) gene clusters, which also encode the peptides with which GarML has the highest sequence identity. However, the inverted organization of the garBCDE and garFGH versus garA and garX units in L. garvieae DCC43 appears to be unique.
Functional analysis of the GarML gene cluster. To investigate the biological roles of the different genes of the GarML cluster, we proceeded to make deletion mutants of the putative operons of the GarML gene cluster. For the ⌬garBCDE and ⌬garFGH mutants, this was readily achieved by a classical double-crossover approach. For garX, we failed to delete the gene after several attempts. Instead, a gene inactivation approach was used to generate the garX:: pCG47 strain. We then determined the impact of these genotypes on the production, immunity, and growth of L. garvieae DCC43, the results of which are displayed in Fig. 2 and summarized in Table 2 .
The deletion of the first operon in the GarML gene cluster, garFGH, encoding a putative ABC transporter complex, appeared to have no major impact on either growth of the strain or immunity to or extracellular production of GarML. The immunity was determined to be at the wild-type level (MIC 50 of 320 BU ml Ϫ1 ), as was the extracellular production of GarML. These results suggest that this putative ABC transporter is not required for immunity or production of bacteriocin.
The second operon in the GarML gene cluster, garBCDE, encodes the putative immunity protein as well as two putative membrane proteins and an ATPase. Deletion of this operon had dramatic effects on the phenotype of the producer strain. First, production of GarML was not detected in the ⌬garBCDE mutant (Fig. 2) . Furthermore, it was shown that the immunity of this deletion mutant was lowered 250-fold (MIC 50 ϭ 1.25 BU ml Ϫ1 ; that of the wild-type producer strain was 320 BU ml Ϫ1 ), which is 4-fold lower than the sensitivity level of the indicator strain, L. lactis IL1403 (5 BU ml Ϫ1 ). Together, these results provide strong evidence that the garBCDE operon is vital not only for biosynthesis but also for immunity to GarML.
Lastly, the garX::pCG47 mutant also displayed loss of GarML production and lowered immunity, with an approximately 8-to 16-fold reduction in immunity toward GarML compared to the wild-type producer (Fig. 2) . This mutant was less sensitive to GarML than the ⌬garBCDE mutant, but even so, it is evident that GarX also contributes in some manner to immunity toward extracellularly added GarML.
Proteomic analysis of GarML biosynthesis. To explore the roles of the garBCDE and garX operons in biosynthesis of GarML at the protein level, we performed mass spectrometry analysis of culture supernatants of wild-type producer L. garvieae DCC43 and the deletion/knockout mutants.
For wild-type producer cells and the bacteriocin-positive ⌬garFGH mutant, we were able to detect specific trypsin fragments diagnostic for the circular mature bacteriocin as well as the full-length linear precursor peptide and the processed linear precursor peptide (i.e., without the leader sequence) ( Table 2 ; see Fig.  S1 in the supplemental material). In contrast, only the linear forms were detected for the ⌬garBCDE and garX::pCG47 mutants, which is consistent with the fact that these mutants produce no active bacteriocin (Fig. 2) . Together, these results indicate that the circular structure of the bacteriocin is essential for its antimicrobial activity and that both GarBCDE and GarX are involved in the circularization step that eventually gives rise to mature and active GarML.
DISCUSSION
In this work, we identified and characterized the gene cluster responsible for biosynthesis of and immunity to the circular bacteriocin GarML, which is chromosomally encoded in the producer strain L. garvieae DCC43. Bioinformatic analysis suggests that the gene cluster contains four transcriptional units: the monocistronic garA (bacteriocin precursor) and garX (transmembrane protein) genes and the polycistronic garBCDE (immunity protein and putative transport complex) and garFGH (putative ABC transporter) operons ( Fig. 1 and Table 1 ). The gene cluster shares several traits, both in genetic organization and in the putative functions of the encoded proteins, with other subclass i circular bacteriocin gene clusters (Fig. 1) . Functional analysis combined with mass spectrometry of deletion mutants of these operons revealed new insights into the biosynthesis of GarML, which may thus apply to subclass i circular bacteriocins in general.
Deletion of the garFGH operon did not have any significant effect on either the production of mature GarML or immunity (Fig. 2) , and thus this operon is evidently nonessential to GarML biosynthesis. The corresponding genes (AS-48FGH) in the producer strain of enterocin AS-48 were not at first identified as part of the gene cluster encoding this bacteriocin; however, they were later shown to provide a small increase in both production of and immunity to enterocin AS-48 (21) . It is possible that GarFGH functions as a secondary transporter of GarML to prevent extracellular GarML from penetrating the cell envelope, in a manner similar to the immunity-providing ABC transporters of many lantibiotics (41) . However, our experimental results did not support this notion, as the presence of the intact garFGH operon did not compensate for the loss of immunity resulting from deletion of the garBCDE operon or the garX gene. The corresponding ABC transporters encoded by the carnocyclin A and circularin A gene clusters have also been shown to be nonessential for bacteriocin production and immunity (20, 22) . Thus, we are unable to ascribe any function to the GarFGH complex at this time. However, based on the apparent conservation of these ABC transporters between circular bacteriocin subclass i gene clusters (Fig. 1) , in addition to the known function of the corresponding complex in enterocin AS-48 (21), it is possible that an independent function or accessory role of GarFGH will be elucidated at a later stage.
By mass spectrometry, we were able to detect all three forms of the GarML peptide in the culture supernatant of the wild-type producer strain (Table 2 ; see Fig. S1 in the supplemental material) and the bacteriocin-positive ⌬garFGH mutant (results not shown): the mature circular peptide as well as the full-length linear peptide with the three-amino-acid leader sequence (MFD) and the linear peptide without the leader sequence. As expected, we were not able to detect the circular form of GarML in the bacteriocin-negative ⌬garBCDE and garX::pCG47 mutants, although both these mutants contained the linear forms of GarML. Based on these observations, it appears likely that both the ⌬garBCDE and garX::pCG47 mutants have lost the ability to perform the circularization step, which appears to be essential for the antimicrobial activity of GarML.
For most class II linear bacteriocins, including lactococcin G (class IIb) and lactococcin A (class IId), a dedicated membranelocated ABC transporter is responsible for the removal of the leader sequence from the precursor peptide and the concurrent export of the mature peptide out of the cell (42) (43) (44) . For class II circular bacteriocins like GarML, however, little is known about the process behind their maturation. Nevertheless, it is generally believed that the maturation of circular bacteriocins consists of three events, i.e., removal of the leader peptide, circularization, and export, and that these three events take place either in a de- fined order in a stepwise fashion or in a coordinated one-step reaction. However, the specific sequence of events and potential coupling of these processes are not known (6, 45) . In the present study, we have shown that, at least for garvicin ML, removal of the leader sequence and circularization are two separate processes, as we could detect the linear processed form of GarML (without a leader) in the two bacteriocin-negative mutants and also in the bacteriocin-positive cells. To our knowledge, this is the first time it has been demonstrated that these processes are independent and, importantly, that leader sequence cleavage takes place before circularization. Furthermore, as the linear peptides were detected in all three mutants (⌬garFGH, ⌬garBCDE, and garX::pCG47) and in wildtype cells, this observation suggests that leader sequence cleavage is most likely executed by a separate functional entity, i.e., one not encoded by garX, garFGH, or garBCDE. However, no candidate protease-or peptidase-encoding genes are located in the vicinity of the GarML gene cluster. The cleavage of the leader sequence must therefore be performed by an as yet unidentified, specific or nonspecific peptidase. Similar ideas have been suggested previously for enterocin AS-48 (46, 47) and may explain the apparent problems in expressing circular bacteriocins outside the genera or species of the original producer (23, 46) and in obtaining stable heterologous production (20) . Resolving this issue could therefore render efficient heterologous expression of circular bacteriocins in industrially relevant species possible.
The detection of linear forms of circular bacteriocins in the supernatant of the producing strain has previously been taken into account for the circularization reaction taking place on the extracellular side of the cytoplasmic membrane (48) . However, in the case of GarML, the results indicate that cell autolysis can explain detection of these species in the culture supernatant, as linear forms of GarML in a few cases were not detectable in supernatants from cells grown in sucrose-stabilized media (results not shown). Consequently, we cannot make any assumptions as to the intra-or extracellular localization of the steps in GarML biosynthesis.
Functional analysis of the ⌬garBCDE and garX::pCG47 mutants revealed that production of functional bacteriocin and immunity were impaired in both strains. This is analogous to the situation for enterocin AS-48, where AS-48B and AS-48C (similar to garX and garD, respectively) have been implicated in biogenesis and immunity (49) . Moreover, mass spectrometry confirmed that neither the ⌬garBCDE nor garX::pCG47 mutant produced the mature circular bacteriocin. The results thus imply that both Gar-BCDE and GarX are involved specifically in the circularization step of GarML biosynthesis, which has not been demonstrated previously for any other circular bacteriocin. The functions of GarBCDE and GarX appear to be nonoverlapping, as neither compensates to any significant extent for inactivation of the other, which would be the expected outcome if these proteins either could perform circularization or provide immunity separately. If one operon were responsible for circularization and the other for immunity, one would expect to observe immunity without production in one strain and to detect circular bacteriocin and/or observe detrimental growth effects in the strain without the immunity determinant(s), which was not the case. Our results strongly suggest that circularization does not occur, and that immunity is severely affected, without the presence of both Gar-BCDE and GarX. Consequently, it is likely that these proteins are linked, either functionally or by regulation, to provide both immunity to and biosynthesis of GarML. In other circular bacteriocin clusters, the genes corresponding to garX and garD are carried by the same polycistronic transcript (19, 20) (Fig. 1) , thus supporting the possible link between the encoded proteins. Coproduction and/or coregulation of the immunity and biosynthetic machinery is indeed common in bacteriocin production (41, 50) , forming a strategy which is clearly advantageous for the producer organism. In the GarML gene cluster, however, there are no encoded proteins which display similarity to known regulatory domains. We therefore believe that GarX and GarBCDE are functionally linked, possibly by forming a multicomplex in the cell membrane, to perform circularization of the linear peptide into the mature circular form, most likely concomitant with export out of the cell.
In conclusion, based on these results, a possible model for GarML biosynthesis is postulated (Fig. 3) . In this model, the Nterminal three amino acid residues (MFD) of the precursor peptide are cleaved off by an unknown peptidase. The linear peptide is subsequently exported out of the cell, with concomitant circularization by a GarCDE and GarX multicomplex, which could act in a defined coupled sequence or as a single functional unit. The mature and active bacteriocin is then released into the extracellular space. By analogy to other circular bacteriocin immunity proteins (19, 20, 22) , GarB likely constitutes the primary immunity determinant, but full immunity requires the entire multicomplex.
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FIG 3
Proposed model for biosynthesis of GarML in L. garvieae DCC43. The N-terminal three amino acid residues (represented by mauve spheres) of the precursor peptide are cleaved off by an unknown peptidase. The linear peptide is subsequently exported out of the cell, with concomitant circularization by a GarCDE and GarX multicomplex. The mature and active bacteriocin is then released into the extracellular space. GarB is likely the primary immunity determinant providing host self-protection toward GarML; however, full immunity requires the entire multicomplex.
